Pioneer Trust Bank N A OR decreased its stake in shares of Baxter International Inc (NYSE:BAX) by 18.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,665 shares of the medical instruments supplier’s stock after selling 815 shares during the quarter. Pioneer Trust Bank N A OR’s holdings in Baxter International were worth $237,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in BAX. Parametric Portfolio Associates LLC lifted its position in Baxter International by 71.1% during the second quarter. Parametric Portfolio Associates LLC now owns 1,632,846 shares of the medical instruments supplier’s stock worth $98,852,000 after buying an additional 678,429 shares in the last quarter. Acadian Asset Management LLC lifted its position in Baxter International by 156.7% during the fourth quarter. Acadian Asset Management LLC now owns 657,855 shares of the medical instruments supplier’s stock worth $42,523,000 after buying an additional 401,532 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in Baxter International by 35.8% during the third quarter. Canada Pension Plan Investment Board now owns 1,413,054 shares of the medical instruments supplier’s stock worth $88,669,000 after buying an additional 372,500 shares in the last quarter. Segall Bryant & Hamill LLC increased its stake in Baxter International by 209.0% during the third quarter. Segall Bryant & Hamill LLC now owns 412,054 shares of the medical instruments supplier’s stock worth $25,856,000 after acquiring an additional 278,685 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in Baxter International by 619.2% during the third quarter. Nordea Investment Management AB now owns 188,842 shares of the medical instruments supplier’s stock worth $11,850,000 after acquiring an additional 162,584 shares during the last quarter. Hedge funds and other institutional investors own 83.82% of the company’s stock.

In related news, SVP Giuseppe Accogli sold 28,641 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Third Point Llc sold 5,000,000 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $64.23, for a total value of $321,150,000.00. The disclosure for this sale can be found here. Insiders sold 5,061,991 shares of company stock valued at $325,245,035 over the last ninety days. Insiders own 0.05% of the company’s stock.

BAX has been the subject of several recent analyst reports. Evercore ISI initiated coverage on Baxter International in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $71.00 target price for the company. Bank of America raised Baxter International from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 2nd. Raymond James Financial raised Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 target price for the company in a research note on Wednesday, January 3rd. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $69.00 target price for the company in a research note on Tuesday, October 10th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $65.00 target price on shares of Baxter International in a research note on Thursday, October 26th. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $68.64.

Shares of Baxter International Inc (NYSE BAX) opened at $69.20 on Friday. Baxter International Inc has a one year low of $45.47 and a one year high of $69.65. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $37,157.53, a price-to-earnings ratio of 37.20, a PEG ratio of 2.05 and a beta of 0.69.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The business had revenue of $2.71 billion during the quarter, compared to analysts’ expectations of $2.66 billion. During the same period in the previous year, the firm posted $0.56 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. sell-side analysts predict that Baxter International Inc will post 2.43 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, January 2nd. Stockholders of record on Friday, December 1st were paid a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.92%. Baxter International’s payout ratio is presently 34.41%.

TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/pioneer-trust-bank-n-a-or-has-237000-position-in-baxter-international-inc-bax/1813628.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.